Published August 2019 | Version v1
Journal article

MicroRNA-21 is Required for Hematopoietic Cell Viability After Radiation Exposure

  • 1. Medical Scientist Training Program, Vanderbilt University School of Medicine, Nashville (United States)
  • 2. Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia (United States)
  • 3. Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas (United States)
  • 4. Department of Radiation Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia (United States)

Description

Radiation therapy is an essential intervention used in the treatment of more than half of cancer patients. With the increasing use of hypofractionated radiation regimens, concurrent use of radiation and chemotherapy, targeted agents and immunotherapy, the risk of radiation-induced toxicities is increased. However, much remains unknown about the molecular underpinnings responsible for radiation-induced toxicity. MicroRNA (miRNA) are small, non-coding RNA involved in post-transcriptional regulation of gene expression. miR-21 is an oncomiR that is dysregulated in a significant fraction of human malignancies, and its overexpression is linked to poor overall survival, chemoresistance, and radioresistance in several human cancers. However, the contribution of miR-21 in governing radiation sensitivity in normal, untransformed cells, and the impact of silencing this miRNA in normal tissues remains largely unexplored.

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2019.04.020;
PII
S0360301619306522;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
104
Journal Issue
5
Journal Page Range
p. 1165-1174
ISSN
0360-3016
CODEN
IOBPD3

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
55057350
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
ANIMAL TISSUES; CHEMOTHERAPY; HEALTH HAZARDS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PATIENTS; RADIOSENSITIVITY; RADIOTHERAPY; RNA; TOXICITY; VIABILITY
Descriptors DEC
ANIMALS; BODY; DISEASES; HAZARDS; MAMMALS; MEDICINE; NUCLEAR MEDICINE; NUCLEIC ACIDS; ORGANIC COMPOUNDS; PRIMATES; RADIOLOGY; SENSITIVITY; THERAPY; VERTEBRATES

Optional Information

Copyright
Copyright (c) 2019 Published by Elsevier Inc.